Why the study?
Current recommendations state rivaroxaban does not require coagulation monitoring, prompting an exploration into whether monitoring should remain unnecessary for all patients and how coagulation abnormalities relate to bleeding.
Does oral rivaroxaban cause bleeding and coagulation abnormalities in a patient with atrial fibrillation, deep venous thrombosis, and acute pulmonary embolism?
Does oral rivaroxaban cause bleeding and coagulation abnormalities in a patient with atrial fibrillation, deep venous thrombosis, and acute pulmonary embolism?
This case report highlights that despite current guidelines, some patients may develop significant bleeding and coagulation abnormalities on rivaroxaban, suggesting a potential role for monitoring in select cases.
May warrant coagulation monitoring in select rivaroxaban patients; leaves open whether routine testing improves safety.
BACKGROUND: Rivaroxaban is a non-vitamin K antagonist oral anticoagulant that does not require coagulation monitoring based on current recommendations. Our goal is to explore whether routine coagulation monitoring should not be required for all patients receiving oral rivaroxaban, what relationship between routine coagulation abnormalities and bleeding, and how to deal with the above clinical situations through our case and review of the literature. CASE SUMMARY: We report a 67-year-old woman with a history of atrial fibrillation who presented to the hospital with worsening dyspnea and cough. Based on electrocardiogram, venous compression ultrasonography, and computed tomography pulmonary angiography, the diagnosis of atrial fibrillation, deep venous thrombosis, and acute pulmonary embolism was confirmed. Her coagulation assays and renal function were normal on admission; she was not underweight, did not have a history of hemorrhagic disease, and her CHA2DS2-VAS, HAS-BLED, and simplified Pulmonary Embolism Severity Index scores were 3, 0, and 0, respectively. Oral rivaroxaban (15 mg twice daily) was administered. The following day, she presented gastrointestinal and gum bleeding, combined with coagulation abnormalities. Following cessation of rivaroxaban, her bleeding stopped and tests improved over the next 2 d. Rivaroxaban was begun again 3 d after recovery. However, she again presented with gastrointestinal and gum bleeding and the abnormal tests, and the therapy was discontinued. At 30-d follow-up after discharge, she presented normal coagulation tests without bleeding. CONCLUSION: Although current guidelines recommend that using non-vitamin K antagonist oral anticoagulants including rivaroxaban do not require coagulation monitoring, a small number of patients may develop routine coagulation test changes and bleeding during rivaroxaban therapy, especially in the elderly. Clinicians should pay attention to these patients and further obtain evidence in practice.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: